Abstracts tagged "Lipids"

Abstract Number: 115 • 2015 ACR/ARHP Annual Meeting
Validation of a Large Rheumatoid Arthritis Cohort and Preventive Health Screening
Michael Grasso¹, Dana Direnzo², Yelena Yesha³, Naphtali Rishe⁴ and Amanda Niskar⁵, ¹Emergency Medicine, University of Maryland School of Medicine, Baltimore, MD, ²Internal Medicine, University of Maryland Medical Center, Baltimore, MD, ³Computer Science and Electrical Engineering, Professor, Baltimore, MD, ⁴Computer Science, Florida International University, Miami, FL, ⁵1330 West Peachtree Street NW, Arthritis Foundation, Atlanta, GA
Background/Purpose: We extracted a large cohort of rheumatoid arthritis (RA) patients, on which we plan to apply big data analytics for earlier diagnosis of RA.…
Abstract Number: 1440 • 2014 ACR/ARHP Annual Meeting
Asymptomatic Carotid Plaques in RA Patients Are Associated with Increased HDL Function
Silvia Rollefstad¹, Bente Halvorsen², Tonje Skarpengland², Sella Provan³, Tore K. Kvien⁴ and Anne Grete Semb¹, ¹Preventive Cardio-Rheuma clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴PsAID taskforce, EULAR, Zurich, Switzerland
Background/Purpose Reverse cholesterol transport (RCT) is a major anti atherogenic function of high density lipoprotein cholesterol (HDL) and has been shown to be related to…
Abstract Number: 1361 • 2014 ACR/ARHP Annual Meeting
Rheumatologists’ Attitudes on Cardiovascular Risk and Lipid Screening in Patients with Rheumatoid Arthritis at an Academic Medical Center
Ashwini Komarla¹ and Alexis Ogdie², ¹Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Cardiovascular (CV) disease is a major cause of morbidity and mortality in the rheumatoid arthritis (RA) population. Thus, the recognition and management of cardiovascular…
Abstract Number: 1274 • 2014 ACR/ARHP Annual Meeting
Patients with Osteoarthritis Do NOT Have Increased Risk of Cardiovascular Disease in Ullensaker Community in Norway
Silvia Rollefstad¹, Ingvild Eeg², Ida K. Haugen², Inge C. Olsen³, Nina Østerås⁴, Barbara Christensen², Hilde Berner Hammer⁵, Lars Nordsletten⁶, Bård Natvig⁷, Tore K. Kvien⁸ and Anne Grete Semb¹, ¹Preventive Cardio-Rheuma clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Department of rheumatology, National Advisory Unit for rehabilitation in rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Postboks 23 Vinderen, Diakonhjemmet Hospital, Oslo, Norway, ⁶Dept of Orthopaedic Surgery, Oslo University Hospital, Oslo, Norway, ⁷General Practice, Oslo University, Oslo, Norway, ⁸Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose Controversies exist regarding whether patients with osteoarthritis (OA) have an increased risk of cardiovascular (CV) disease. Our aim was to evaluate the CV risk…
Abstract Number: 1123 • 2014 ACR/ARHP Annual Meeting
Impact of Genes Modulating Serum Low-Density Lipoprotein Cholesterol Levels on Progression of Joint Destruction in Japanese Patients with Rheumatoid Arthritis
Shinji Yoshida¹, Katsunori Ikari¹, Koichiro Yano¹, Yoshiaki Toyama², Atsuo Taniguchi³, Hisashi Yamanaka¹ and Shigeki Momohara³, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Department of Orthopaedic Surgery, Keio University School of Medicine, Tokyo, Japan, ³Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose Patients with rheumatoid arthritis (RA) have a higher prevalence of dyslipidemia than healthy individuals. Since RA is a chronic inflammatory disease, an inflammatory response…
Abstract Number: 1063 • 2014 ACR/ARHP Annual Meeting
Management of Hyperlipidemia Among Patients with Rheumatoid Arthritis in the Primary Care Setting
Kashif Jafri¹, Lynne Taylor², Nehal N. Mehta³, Melissa Nezamzadeh⁴, Joshua Baker⁵ and Alexis Ogdie⁶, ¹Department of Medicine, University of Pennsylvania, Philadelphia, PA, ²Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, ³Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Medicine/Rheumatology, University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA, ⁶Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Rheumatoid arthritis has been associated with an increased risk of cardiovascular morbidity and mortality. It is unclear, however, whether this knowledge has translated into…
Abstract Number: 487 • 2014 ACR/ARHP Annual Meeting
Assessment of Lipid Changes in Patients with Early Rheumatoid Arthritis Treated with Tofacitinib or Methotrexate over 24 Months
C. Charles-Schoeman¹, A. Dikranian², J. Taylor³, B. Wilkinson⁴, T. Jones⁵, K. Kwok⁶ and C. Nduaka⁴, ¹University of California, Los Angeles, CA, ²San Diego Arthritis Medical Clinic, San Diego, CA, ³Anderson Arthritis and Rheumatology Center, Meridian, MS, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Post-baseline (BL) increases in mean low-density lipoprotein cholesterol (LDL-C) and…
Abstract Number: 2465 • 2014 ACR/ARHP Annual Meeting
Cyclic Phosphatidic Acid (cPA) Suppresses MMP-3, a Disintegrin and Metalloproteinase with Thrombospondin Motifs(ADAMTS)-4, -5 and Stimulates HAS2 Expression in Inflammatory Rheumatoid Synovial Fibroblasts Induced with IL-1β and/or TNF-α
Ikuko Masuda^1,2, Kodo Okada³, Hisashi Yamanaka⁴ and Shigeki Momohara⁴, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Rheumatology, Jyujyo Takeda Rehabilitation Hospital, Kyoto, Japan, ³SANSHO, Co. Ltd., Tokyo, Japan, ⁴Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose Cyclic phosphatidic acid (cPA) is one of bioactive lipid, has been implicated as an mediator of various biological effects including i) antiproliferative effect on…
Abstract Number: 2305 • 2014 ACR/ARHP Annual Meeting
Improving Screening for Hyperlipidemia in Patients with Rheumatoid Arthritis at an Academic Rheumatology Practice
Ashwini Komarla¹ and Alexis Ogdie², ¹Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose Cardiovascular disease is the leading cause of mortality in the rheumatoid arthritis (RA) population. However, cardiovascular risk factors such as hyperlipidemia are undertreated in…
Abstract Number: 1441 • 2014 ACR/ARHP Annual Meeting
Accelerated Aging in DMARD and Treatment Naive Early Rheumatoid Arthritis Patients Measured By a Stem Cell Assay Is Associated with Increased LDL and Is Linked to Impaired Cardiopulmonary Function
Torkell Ellingsen^1,2,3, Henriette Jørgensen⁴, Dino Demirovic⁴, Lone Deibjerg⁵, Frank Andersen⁵, Agnete Hedemann-Andersen⁵, Brian Bridal Løgstrup^5,6 and Suresh Rattan⁴, ¹Diagnostic Centre Region, Hospital Silkeborg Denmark, Odense, Denmark, ²The Danish National Registry DANBIO, Odense, Denmark, ³Department of Rheumatology, Odense University Hospital, Denmark, Odense, Denmark, ⁴Laboratory of Cellular Ageing, Institute of Molecular Biology and Genetics, Århus University, Århus, Denmark, ⁵Diagnostic Centre Region, Hospital Silkeborg Denmark, Silkeborg, Denmark, ⁶Cardiology, Skejby Hospital, Århus Universityhosital, Århus, Denmark
Background/Purpose: The cardiovascular comorbidity seen in early treatment naive rheumatoid arthritis (RA) can be considered as an aspect of ´´accelerated aging``. Methods: We investigated cell…
Abstract Number: 2827 • 2013 ACR/ARHP Annual Meeting
Effect Of Biologic Agents On Lipids and Cardiovascular Risk In Rheumatoid Arthritis Patients
Dimitrios A. Pappas¹, Ani John², Jeffrey R. Curtis³, George W. Reed⁴, Jeffrey D. Greenberg⁵, Ashwini Shewade², Daniel H. Solomon⁶, Joel M. Kremer⁷ and Tanya Sommers⁴, ¹Columbia University, New York, NY, ²Genentech Inc., South San Francisco, CA, ³Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴CORRONA, Inc., Southborough, MA, ⁵Departments of Medicine (Rheum Div) and Hospital for Joint Diseases, New York Hospital for Joint Diseases, New York, NY, ⁶Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, ⁷Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY
Background/Purpose: The risk for cardiovascular disease (CVD) is increased in patients (pts) with RA. The interplay between traditional CV risk factors and inflammatory burden may…
Abstract Number: 2332 • 2013 ACR/ARHP Annual Meeting
Assessment of Lipid Changes and Infection Risk In Diabetic and Nondiabetic Patients With Rheumatoid Arthritis Treated With Tofacitinib
W. F. C. Rigby¹, L. Takiya², S. P. Wood³, H. Fan² and T. V. Jones², ¹Medicine, Geisel School of Medicine at Dartmouth, Lebanon, NH, ²Pfizer Inc, Collegeville, PA, ³Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Studies have shown an increased prevalence of diabetes mellitus…
Abstract Number: 2309 • 2013 ACR/ARHP Annual Meeting
Quantifying The Gap Between General Population Guidelines and Expert Opinion For Cardiovascular Risk Management In Rheumatic Disease Patients
Katherine P. Liao¹, Jonathan Brown², Jonathan S. Coblyn³, Paul Cohen², Jorge Plutzky² and Daniel H. Solomon⁴, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Cardiology, Brigham and Women's Hospital, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA
Background/Purpose: Cardiovascular (CV) risk is higher among rheumatic disease patients than the general population. However, CV risk management guidelines calibrated for the rheumatic disease population…
Abstract Number: 1280 • 2013 ACR/ARHP Annual Meeting
The Role of Sphingosine-1-Phosphate Receptor 3 Signaling in Murine Collagen-Induced Arthiritis
Hidetake Nagahara¹, Masataka Kohno¹, Ken Murakami¹, Aihiro Yamamoto¹, Takahiro Seno¹, Wataru Fujii¹, Kazuki Fujioka¹, Yuji Kukida¹, Ryo Oda², Hiroyoshi Fujiwara² and Yutaka Kawahito¹, ¹Department of Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, ²Department of Orthopaedics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, kyoto, Japan
Background/Purpose: Sphingolipids represent a major class of lipids that are ubiquitously expressed in eukaryotic cell membranes. Through the interaction with a family of five G-protein-coupled…
Abstract Number: 1166 • 2013 ACR/ARHP Annual Meeting
Anti-Inflammatory Property Of HDL In NOD1 Ligand Induced Kawasaki Arteritis In Mice
Hajime Kono¹, Tamiko Yanagida², Kurumi Asako¹, Toshihiro Nanki¹, Hirotoshi Kikuchi¹, Akiko Okamoto¹, Akiko Onda³ and Maki Takayama¹, ¹Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ²Depart ment of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ³Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan
Background/Purpose: Atherosclerosis is a chronic metabolic disease of inflammatory processes. Immune cells including monocytes are recruited to the subintimal lesion of the vascular wall and…